In view of the limited therapeutic efficacy with single agent LAG-3 antibodies seen in the current study and in other studies as described above, studies evaluating INCAGN02385 combination therapies with retifanlimab (anti–PD-1 mAb) and INCAGN02390 (anti–TIM-3 mAb) are underway and will help to elucidate the contribution of these antibodies to immunotherapy tumor response. Here, HAVCR2 is linked to neoplasm.